Aggregated price index with volume information
Summary:
- Antibiotic Developers stocks up 3.0% on average while median return up 0.2% in a day
- Antibiotic Developers stocks up 7.8% on average while median return up 6.7% in a week
- Antibiotic Developers stocks up 1.6% on average while median return up 2.9% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $SPRO 4.2%
- 1M losers are : Losers for past month are $SMMT -9.1%
- 1W winners are : Winners for past week are $SMMT 16.1%
- 1W losers are : Losers for past week are
Correlation Analysis
Index correlation analysis
Correlation for the past month is 6.3%, for the past 3 months is 8.1%
In the past month for a 5 days rolling window, the highest corrrelation is 44.4%, the lowest correlation is -21.7%, the latest correlation is 10.3%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 25.2% between PRTK and SMMT
The lowest correlation is -7.5% between MRK and SMMT
Insiders who purchased Summit Therapeutics Inc. ( NASDAQ:SMMT ) shares in the past 12 months are unlikely to be deeply...
MIAMI, March 22, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced promising data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, that is being presented today at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic. Two posters featuring updated ivonescimab data will be displayed from 12:00 to 12:45pm Central European Time. The posters will also be made available on our website after
Several blood thinners are being developed that could prevent the clots that cause heart attacks and strokes—without some of the side effects.
In this article, we discuss 11 best healthcare ETFs to buy now. If you want to skip our discussion on the healthcare industry, head over to 5 Best Healthcare ETFs To Buy Now. In 2023, the healthcare sector faced challenges as investors adjusted portfolios in anticipation of higher interest rates. Although the sector lagged behind […]
It's been a good week for Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders, because the company has just released...
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript March 13, 2024 Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.96, expectations were $-0.1. SPRO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to the […]
Most readers would already be aware that Spero Therapeutics' (NASDAQ:SPRO) stock increased significantly by 35% over...
MIAMI, March 14, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic. Two posters featuring updated ivonescimab data will be displayed on Friday, March 22 from 12:00 to 12:45pm Central European Time.
Q4 2023 Spero Therapeutics Inc Earnings Call
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 633.33% and 278.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?